Addressing potential prior-data conflict when using informative priors in proof-of-concept studies.

导出 LinkOut

翻译打印收藏纠错

作者： Timothy,Mutsvari ^[1] ; Dominique,Tytgat ^[2] ; Rosalind,Walley ^[3]

作者单位： UCB BioPharma SPRL, Global Exploratory Development, Chemin du Foriest, Belgium, B-1420 Braine-l'Alleud, (currently at Arlenda S.A., 93 Chaussée Verte, 4470 Saint-Georges sur Meuse, Belgium). ^[1] UCB BioPharma SPRL, Global Exploratory Development, Chemin du Foriest, B-1420 Braine-l'Alleud, Belgium, (currently at Clinical Pharmacokinetics/Pharmacometrics, Sanofi-Aventis Deutschland GmbH, Frankfurt am Main, Germany). ^[2] UCB Pharma, Global Exploratory Development, 208 Bath Road, Slough, Berkshire SL1 3WE, UK. ^[3]

关键词 Bayesian analysis informative prior mixture prior prior-data conflict proof-of-concept robust prior

主题词贝叶斯定理(Bayes Theorem);临床试验, Ⅱ期(主题)(Clinical Trials, Phase II as Topic);人类(Humans);模型, 统计学(Models, Statistical);统计学(主题)(Statistics as Topic)

DOI 10.1002/pst.1722

PMID 26762570

发布时间 2017-11-27

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览13

Pharmaceutical statistics

28-36页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Addressing potential prior-data conflict when using informative priors in proof-of-concept studies.

Pharmaceutical statistics

相似文献

Pharmaceutical statistics

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Addressing potential prior-data conflict when using informative priors in proof-of-concept studies.

Pharmaceutical statistics

相似文献

Pharmaceutical statistics

相关期刊

检索历史清除